San Francisco, CA (June 11, 2012) – Dennis J. Canty of Kaiser Gornick LLP was recently appointed to the Plaintiff’s Steering Committee for the California Judicial Council Coordinated Proceeding related to the drug ACTOS.

ACTOS (pioglitazone) is a drug marketed by Takeda Pharmaceuticals to treat diabetes. The use of ACTOS has been linked to an increased risk of bladder cancer. The serious side effects associated with ACTOS have caused some Western European countries to suspend the sale of the drug. In June and August of 2011, the U.S. Food and Drug Administration issued warnings and required updated drug labeling concerning the risk of bladder cancer with Actos.

Mr. Canty is an experienced litigator with extensive experience in product liability cases involving dangerous pharmaceuticals and medical devices.

Kaiser Gornick LLP is a San Francisco-based law firm that represents individuals injured by defective products and fraudulent business practices.